Brown C A, Mahuran D J
Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.
J Biol Chem. 1991 Aug 25;266(24):15855-62.
Lysosomal beta-hexosaminidase (EC 3.2.1.52) occurs as two major isoenzymes, hexosaminidases A (alpha beta) and B (beta beta). The alpha- and beta-subunits are encoded by the HEXA and HEXB genes, respectively. Extensive homology in both the gene structures and deduced primary sequences demonstrate their common evolutionary origin. Defects in the alpha- or beta-subunits lead to Tay-Sachs of Sandhoff disease, respectively. The B1 variant of Tay-Sachs disease is characterized by an unusual phenotype. Patient samples contain both isoenzymes; however, hexosaminidase A lacks activity toward alpha-specific substrates. In a previous report, we analyzed the biochemical consequences of an Arg178----His substitution in the alpha-subunit, causing the B1 phenotype, by in vitro mutagenesis of the homologous codon for Arg211 in the beta-subunit to produce His. We found that the substitution did not affect dimer formation or cellular targeting but caused a near total loss of activity toward a common alpha- and/or beta-substrate. Additional effects were also noted that suggested a perturbation had occurred to the protein's secondary structure. In this report, we investigate further the role of Arg in the catalysis of hexosaminidase substrates. The introduction of more or less conservative amino acid substitutions at the beta-Arg211 site were evaluated in terms of their effects on the protein's catalytic activity and susceptibility to the arginine-specific reagents and on its stability and rate of maturation in the cell's lysosome. These data demonstrate that the changes in the in vivo stability and rate of maturation, previously noted with the Arg211----His substitution, are independent of the loss in enzymatic activity. Whereas treatment of purified normal human placental hexosaminidases A and B with arginine-specific modifying reagents produced a time-dependent loss of enzymatic activity toward both alpha-specific and common substrates, these reagents failed to significantly decrease the residual activities of mutant proteins lacking Arg at position 211. Kinetic analysis of the residual enzyme activity from our most conservative construct, Arg211----Lys, determined an apparent Vmax approximately 400-fold reduced from that of the wild type enzyme but detected no change in the apparent Km. Additionally, the pH optimum of this mutant enzyme was narrower and slightly more basic than that of the normal enzyme. Thus, Arg211 in the beta-subunit and, by extrapolation, the Arg178 in the alpha-subunit of beta-hexosaminidase are "active" residues, i.e. part of the catalytic sites, but do not participate in substrate binding.
溶酶体β - 氨基己糖苷酶(EC 3.2.1.52)以两种主要同工酶形式存在,即氨基己糖苷酶A(αβ)和B(ββ)。α亚基和β亚基分别由HEXA和HEXB基因编码。基因结构和推导的一级序列中的广泛同源性表明它们有共同的进化起源。α亚基或β亚基的缺陷分别导致泰 - 萨克斯病或桑德霍夫病。泰 - 萨克斯病的B1变异型具有不寻常的表型。患者样本中含有两种同工酶;然而,氨基己糖苷酶A对α特异性底物缺乏活性。在先前的一份报告中,我们通过将β亚基中对应于Arg211的同源密码子进行体外诱变产生His,分析了α亚基中Arg178→His替换导致B1表型的生化后果。我们发现该替换不影响二聚体形成或细胞靶向,但导致对常见α和/或β底物的活性几乎完全丧失。还注意到其他影响,提示蛋白质二级结构发生了扰动。在本报告中,我们进一步研究Arg在β - 氨基己糖苷酶底物催化中的作用。评估了在β - Arg211位点引入或多或少保守的氨基酸替换对蛋白质催化活性、对精氨酸特异性试剂的敏感性以及对其在细胞溶酶体中的稳定性和成熟速率的影响。这些数据表明,先前在Arg211→His替换中观察到的体内稳定性和成熟速率的变化与酶活性的丧失无关。用精氨酸特异性修饰试剂处理纯化的正常人胎盘氨基己糖苷酶A和B会导致对α特异性和常见底物的酶活性随时间丧失,而这些试剂未能显著降低在211位缺乏Arg的突变蛋白的残余活性。对我们最保守构建体Arg211→Lys的残余酶活性进行动力学分析,确定其表观Vmax比野生型酶降低了约400倍,但未检测到表观Km的变化。此外,该突变酶的最适pH范围比正常酶更窄且略偏碱性。因此,β - 氨基己糖苷酶β亚基中的Arg211以及由此推断的α亚基中的Arg178是“活性”残基,即催化位点的一部分,但不参与底物结合。